News

Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan

Fresh off signing up to buy Durata Therapeutics for $675 million, Actavis is making another overture for the embattled Allergan, Reuters reports, potentially setting up a bidding war with the dogged Valeant Pharmaceuticals.

Levicept emerges from Pfizer's R&D ashes with $20M and a new pain drug

Rescued from Pfizer's sweeping R&D cuts, Levicept's lead drug is a protein with promise in chronic pain, and the biotech has raised $15.7 million in venture and grant funding to follow through on its potential.

Top 7 life sciences public investors

It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the...

Chimerix scores promising antiviral data from a controversy-fueled PhIII pilot

Chimerix reports that its pilot Phase III study of the powerful antiviral brincidofovir has posted promising preliminary data, cutting the risk of death from lethal adenovirus infections by as much as half or more.

Chimerix, FDA scramble to launch a new clinical study of brincidofovir for Ebola

Back in March, Chimerix hustled to put together a small Phase III pilot program to test its closely watched antiviral brincidofovir for adenovirus infections. Today, CEO Michelle Berrey says the company is now scrambling to put together another overnight study plan for Ebola rather than risk getting hit with a fresh round of compassionate-use demands.

Positive PhIII PONV study brings little Acacia to a crossroads

Acacia Pharma says it gleaned positive results from a Phase III study of its experimental therapy designed to prevent postoperative nausea and vomiting. And now it's brought in the investment banker J.P. Morgan Cazenove to advise the board on what its next steps should be as it tries to position the treatment for regulatory approval and commercialization.

Bellicum puts up $50M for Ariad's R&D tech

Bellicum Pharmaceuticals has switched up its deal with Ariad Pharmaceuticals, agreeing to hand over $50 million for a no-strings-attached license to some cell-signaling technology.

In a surprise move, Bristol-Myers drops U.S. approval plans for hep C combo

Bristol-Myers Squibb is pulling out of one key race in the global scramble to develop new blockbuster hepatitis C cocktails.

Another CRO heads to Wall Street as INC swings for $150M

Following a trend among the companies that do Big Pharma's heavy lifting, global CRO INC Research has filed to go public, looking to raise $150 million.

With help from Eli Lilly, TVM pushes its build-to-buy fund to $201M

Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.

Hyperion and Clal come to temporary terms over a $570M biotech boondoggle

Hyperion Therapeutics, which claims it was duped into a $570 million deal for an Israeli biotech, has reached a temporary agreement with the seller, calling off its lawyers for the moment while the two try to determine whether the drug at the heart of the acquisition has any future.

Biotech backer Forbion raises $120M toward a new VC fund

The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs.

Alcobra says its ADHD drug works--as long as you don't compare it to placebo

Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo--but only after the company removed data from four "extreme" responders from its analysis.

Struggling Teva slashing R&D, chops 14 programs as it retreats on two fronts

Troubled Teva is circling its research wagons around CNS and respiratory diseases, carving out more than $500 million in research costs over the next three years with plans to shelve or spin out 14 clinical programs as it retreats from women's health and oncology.

Sunesis shares crushed in a rout after leukemia PhIII ends in defeat

Shares of South San Francisco-based Sunesis were crushed this morning after the biotech put out word that its drug vosaroxin had flunked a Phase III test for acute myeloid leukemia. The stock plunged about 70% on the news that the experimental therapy had failed to significantly improve survival rates compared to a placebo.

Actavis snaps up Durata, newly approved antibiotic in $675M buyout

Buyout-hungry Actavis--which is alternatively spotlighted as both a buyer and a possible buyout target--has snapped up Chicago-based Durata Therapeutics and its recently approved antibiotic Dalvance (dalbavancin) for $675 million plus a potential bonus.

UPDATED: Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up

Novartis is prepping new studies that will test how well three of its oncology drugs--the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia--do when combined with Bristol-Myers Squibb's PD-1 drug nivolumab in a joint attack on non-small cell lung cancer.

Top women in biotech 2014

Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...

IPO hopeful rEVO puts off its plans for a $75M debut

Massachusetts biotech rEVO Biolgoics is postponing its efforts to go public in a $75 million IPO.

Report: Arbor Pharma goes on the block for $1B-plus

Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $1 billion.